Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

One Group's Historical Reflections on DNA Vaccine Development.

Fynan EF, Lu S, Robinson HL.

Hum Gene Ther. 2018 Sep;29(9):966-970. doi: 10.1089/hum.2018.066. Epub 2018 Aug 21.

2.

HIV/AIDS Vaccines: 2018.

Robinson HL.

Clin Pharmacol Ther. 2018 Dec;104(6):1062-1073. doi: 10.1002/cpt.1208. Epub 2018 Oct 9.

3.

Ebola virus - prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine.

Robinson HL, Marzi A.

Expert Rev Vaccines. 2018 Sep;17(9):769-771. doi: 10.1080/14760584.2018.1510775. Epub 2018 Aug 20. No abstract available.

PMID:
30092691
4.

Prevalence of maternal urinary ketones in pregnancy in overweight and obese women.

Robinson HL, Barrett HL, Foxcroft K, Callaway LK, Dekker Nitert M.

Obstet Med. 2018 Jun;11(2):79-82. doi: 10.1177/1753495X17743163. Epub 2017 Dec 5.

5.

Dynamic ErbB4 Activity in Hippocampal-Prefrontal Synchrony and Top-Down Attention in Rodents.

Tan Z, Robinson HL, Yin DM, Liu Y, Liu F, Wang H, Lin TW, Xing G, Gan L, Xiong WC, Mei L.

Neuron. 2018 Apr 18;98(2):380-393.e4. doi: 10.1016/j.neuron.2018.03.018. Epub 2018 Apr 5.

6.

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge.

Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, Lewis GK, Hanley PW, Feldmann H, Robinson HL, Marzi A.

Sci Rep. 2018 Jan 16;8(1):864. doi: 10.1038/s41598-017-19041-y.

7.

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model.

Brault AC, Domi A, McDonald EM, Talmi-Frank D, McCurley N, Basu R, Robinson HL, Hellerstein M, Duggal NK, Bowen RA, Guirakhoo F.

Sci Rep. 2017 Nov 7;7(1):14769. doi: 10.1038/s41598-017-15039-8.

8.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.

Shen X, Basu R, Sawant S, Beaumont D, Kwa SF, LaBranche C, Seaton KE, Yates NL, Montefiori DC, Ferrari G, Wyatt LS, Moss B, Alam SM, Haynes BF, Tomaras GD, Robinson HL.

J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15.

9.

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site.

McCurley NP, Domi A, Basu R, Saunders KO, LaBranche CC, Montefiori DC, Haynes BF, Robinson HL.

PLoS One. 2017 Oct 11;12(10):e0177863. doi: 10.1371/journal.pone.0177863. eCollection 2017.

10.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD; HIV Vaccine Trials Network (HVTN) 094 Study Group.

PLoS One. 2017 Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017.

11.

SOMANZ guidelines for the investigation and management sepsis in pregnancy.

Bowyer L, Robinson HL, Barrett H, Crozier TM, Giles M, Idel I, Lowe S, Lust K, Marnoch CA, Morton MR, Said J, Wong M, Makris A.

Aust N Z J Obstet Gynaecol. 2017 Oct;57(5):540-551. doi: 10.1111/ajo.12646. Epub 2017 Jul 3.

PMID:
28670748
12.

DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.

Thompson M, Heath SL, Sweeton B, Williams K, Cunningham P, Keele BF, Sen S, Palmer BE, Chomont N, Xu Y, Basu R, Hellerstein MS, Kwa S, Robinson HL.

PLoS One. 2016 Oct 6;11(10):e0163164. doi: 10.1371/journal.pone.0163164. eCollection 2016.

13.

High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques.

Kannanganat S, Wyatt LS, Gangadhara S, Chamcha V, Chea LS, Kozlowski PA, LaBranche CC, Chennareddi L, Lawson B, Reddy PB, Styles TM, Vanderford TH, Montefiori DC, Moss B, Robinson HL, Amara RR.

J Immunol. 2016 Nov 1;197(9):3586-3596. Epub 2016 Sep 28.

14.

Editorial overview: Preventive and therapeutic vaccines.

Robinson HL, Mulligan MJ.

Curr Opin Virol. 2016 Apr;17:viii-x. doi: 10.1016/j.coviro.2016.05.006. No abstract available.

PMID:
27283522
15.

Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine.

Chamcha V, Kannanganat S, Gangadhara S, Nabi R, Kozlowski PA, Montefiori DC, LaBranche CC, Wrammert J, Keele BF, Balachandran H, Sahu S, Lifton M, Santra S, Basu R, Moss B, Robinson HL, Amara RR.

Open Forum Infect Dis. 2016 Feb 11;3(1):ofw034. doi: 10.1093/ofid/ofw034. eCollection 2016 Jan.

16.

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.

Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112. Epub 2015 Aug 10.

17.

Poor compliance with community-acquired pneumonia antibiotic guidelines in a large Australian private hospital emergency department.

Robinson HL, Robinson PC, Whitby M.

Microb Drug Resist. 2014 Dec;20(6):561-7. doi: 10.1089/mdr.2014.0064.

PMID:
24950058
18.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14. Epub 2014 Jun 11.

19.

The immune space: a concept and template for rationalizing vaccine development.

Manrique A, Adams E, Barouch DH, Fast P, Graham BS, Kim JH, Kublin JG, McCluskey M, Pantaleo G, Robinson HL, Russell N, Snow W, Johnston MI.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1017-22. doi: 10.1089/AID.2014.0040. Epub 2014 Jun 26.

20.

Local control of repeated-dose rectal challenges in DNA/MVA-vaccinated macaques protected against a first series of simian immunodeficiency virus challenges.

Kannanganant S, Gangadhara S, Lai L, Lawson B, Kozlowski PA, Robinson HL, Amara RR.

J Virol. 2014 May;88(10):5864-9. doi: 10.1128/JVI.00145-14. Epub 2014 Feb 26.

21.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton K, Tomaras GD, Montefiori DC, Sato A, Hural J, DeRosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder SP, Hammer SM, Koblin BA, Pensiero M, Butler C, Moss B, Robinson HL; HVTN 205 Study Group; National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network.

J Infect Dis. 2014 Jul 1;210(1):99-110. doi: 10.1093/infdis/jiu003. Epub 2014 Jan 7.

22.

DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge.

Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, Alicea C, von Gegerfelt A, Huang W, Guan Y, Keele BF, Bess JW Jr, Piatak M Jr, Lifson JD, Williams WT, Shen X, Tomaras GD, Amara RR, Robinson HL, Johnson W, Broderick KE, Sardesai NY, Venzon DJ, Hirsch VM, Felber BK, Pavlakis GN.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2975-80. doi: 10.1073/pnas.1215393110. Epub 2013 Jan 28.

23.

Poor immune responses of newborn rhesus macaques to measles virus DNA vaccines expressing the hemagglutinin and fusion glycoproteins.

Polack FP, Lydy SL, Lee SH, Rota PA, Bellini WJ, Adams RJ, Robinson HL, Griffin DE.

Clin Vaccine Immunol. 2013 Feb;20(2):205-10. doi: 10.1128/CVI.00394-12. Epub 2012 Dec 12.

24.

Protective immunity from a germinal center sanctuary.

Robinson HL, Amara RR.

Nat Med. 2012 Nov;18(11):1614-6. doi: 10.1038/nm.2986.

PMID:
23135510
25.

Non-neutralizing antibodies in prevention of HIV infection.

Robinson HL.

Expert Opin Biol Ther. 2013 Feb;13(2):197-207. doi: 10.1517/14712598.2012.743527. Epub 2012 Nov 6. Review.

PMID:
23130709
26.

Co-expression of HIV-1 virus-like particles and granulocyte-macrophage colony stimulating factor by GEO-D03 DNA vaccine.

Hellerstein M, Xu Y, Marino T, Lu S, Yi H, Wright ER, Robinson HL.

Hum Vaccin Immunother. 2012 Nov 1;8(11):1654-8. doi: 10.4161/hv.21978. Epub 2012 Oct 30. Review.

27.

Mining the mechanisms of an HIV vaccine.

Plotkin SA, Robinson HL, Davenport MP.

Nat Med. 2012 Jul 6;18(7):1020-1. doi: 10.1038/nm.2858. No abstract available.

PMID:
22772554
28.

SIVmac239 MVA vaccine with and without a DNA prime, similar prevention of infection by a repeated dose SIVsmE660 challenge despite different immune responses.

Lai L, Kwa SF, Kozlowski PA, Montefiori DC, Nolen TL, Hudgens MG, Johnson WE, Ferrari G, Hirsch VM, Felber BK, Pavlakis GN, Earl PL, Moss B, Amara RR, Robinson HL.

Vaccine. 2012 Feb 21;30(9):1737-45. doi: 10.1016/j.vaccine.2011.12.026. Epub 2011 Dec 15.

29.

Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.

Pillai VK, Kannanganat S, Penaloza-Macmaster P, Chennareddi L, Robinson HL, Blackwell J, Amara RR.

Vaccine. 2011 Jul 26;29(33):5399-406. doi: 10.1016/j.vaccine.2011.05.083. Epub 2011 Jun 7.

30.

Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Lai L, Kwa S, Kozlowski PA, Montefiori DC, Ferrari G, Johnson WE, Hirsch V, Villinger F, Chennareddi L, Earl PL, Moss B, Amara RR, Robinson HL.

J Infect Dis. 2011 Jul 1;204(1):164-73. doi: 10.1093/infdis/jir199.

31.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, Hural J, DeRosa SC, DeFawe OD, Tomaras GD, Montefiori DC, Xu Y, Lai L, Kalams SA, Baden LR, Frey SE, Blattner WA, Wyatt LS, Moss B, Robinson HL; National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network.

J Infect Dis. 2011 Mar 1;203(5):610-9. doi: 10.1093/infdis/jiq105. Epub 2011 Jan 31.

32.

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Kannanganat S, Nigam P, Velu V, Earl PL, Lai L, Chennareddi L, Lawson B, Wilson RL, Montefiori DC, Kozlowski PA, Moss B, Robinson HL, Amara RR.

J Immunol. 2010 Dec 15;185(12):7262-73. doi: 10.4049/jimmunol.1000751. Epub 2010 Nov 12.

33.

A model to assess the accuracy of detecting arboviruses in mosquito pools.

Vitek CJ, Richards SL, Robinson HL, Smartt CT.

J Am Mosq Control Assoc. 2009 Sep;25(3):374-8.

34.

Working towards an HIV/AIDS vaccine.

Robinson HL.

Hum Vaccin. 2009 Jul;5(7):436-8. No abstract available.

PMID:
19662687
35.

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

Zhao J, Lai L, Amara RR, Montefiori DC, Villinger F, Chennareddi L, Wyatt LS, Moss B, Robinson HL.

J Virol. 2009 May;83(9):4102-11. doi: 10.1128/JVI.02173-08. Epub 2009 Feb 18.

36.

Viral attenuation by design.

Robinson HL.

Nat Biotechnol. 2008 Sep;26(9):1000-1. doi: 10.1038/nbt0908-1000. No abstract available.

PMID:
18779812
37.

Nucleic acid immunizations.

Robinson HL, Pertmer TM.

Curr Protoc Immunol. 2001 May;Chapter 2:Unit 2.14. doi: 10.1002/0471142735.im0214s27. Review.

PMID:
18432766
38.

Comparative studies on in vitro expression and in vivo immunogenicity of supercoiled and open circular forms of plasmid DNA vaccines.

Pillai VB, Hellerstein M, Yu T, Amara RR, Robinson HL.

Vaccine. 2008 Feb 20;26(8):1136-41. doi: 10.1016/j.vaccine.2007.10.023. Epub 2007 Oct 30.

39.
40.

Immunogenicity in macaques of the clinical product for a clade B DNA/MVA HIV vaccine: elicitation of IFN-gamma, IL-2, and TNF-alpha coproducing CD4 and CD8 T cells.

Robinson HL, Sharma S, Zhao J, Kannanganat S, Lai L, Chennareddi L, Yu T, Montefiori DC, Amara RR, Wyatt LS, Moss B.

AIDS Res Hum Retroviruses. 2007 Dec;23(12):1555-62.

PMID:
18160013
41.

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Wyatt LS, Earl PL, Vogt J, Eller LA, Chandran D, Liu J, Robinson HL, Moss B.

Vaccine. 2008 Jan 24;26(4):486-93. Epub 2007 Dec 3.

42.

DNA vaccines: a review of developments.

Webster RG, Robinson HL.

BioDrugs. 1997 Oct;8(4):273-92.

PMID:
18020519
43.

HIV/AIDS vaccines: 2007.

Robinson HL.

Clin Pharmacol Ther. 2007 Dec;82(6):686-93. Epub 2007 Oct 31. Review.

PMID:
17971817
44.

Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus.

Kwissa M, Amara RR, Robinson HL, Moss B, Alkan S, Jabbar A, Villinger F, Pulendran B.

J Exp Med. 2007 Oct 29;204(11):2733-46. Epub 2007 Oct 22.

45.

Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines.

Kannanganat S, Kapogiannis BG, Ibegbu C, Chennareddi L, Goepfert P, Robinson HL, Lennox J, Amara RR.

J Virol. 2007 Nov;81(21):12071-6. Epub 2007 Aug 29.

46.

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

Lai L, Vödrös D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, Villinger F, Wyatt LS, Moss B, Amara RR, Robinson HL.

Virology. 2007 Dec 5;369(1):153-67. Epub 2007 Aug 14.

47.

Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells.

Kannanganat S, Ibegbu C, Chennareddi L, Robinson HL, Amara RR.

J Virol. 2007 Aug;81(16):8468-76. Epub 2007 Jun 6.

48.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge.

Nigam P, Earl PL, Americo JL, Sharma S, Wyatt LS, Edghill-Spano Y, Chennareddi LS, Silvera P, Moss B, Robinson HL, Amara RR.

Virology. 2007 Sep 15;366(1):73-83. Epub 2007 May 16.

49.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

Earl PL, Americo JL, Wyatt LS, Eller LA, Montefiori DC, Byrum R, Piatak M, Lifson JD, Amara RR, Robinson HL, Huggins JW, Moss B.

Virology. 2007 Sep 15;366(1):84-97. Epub 2007 May 11.

50.

Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost.

Liu J, Hellerstein M, McDonnel M, Amara RR, Wyatt LS, Moss B, Robinson HL.

Vaccine. 2007 Apr 12;25(15):2951-8. Epub 2006 Jun 9.

PMID:
17360078

Supplemental Content

Loading ...
Support Center